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Abstract 
Objectives: Therapeutic coma (TC) is advocated in guidelines for management of refractory 
status epilepticus (SE); this is however based on weak evidence. We here address the specific 
impact of TC on SE outcome. 
Design: Retrospective assessment of a prospectively collected cohort. 
Setting: Academic hospital. 
Patients: Consecutive adults with incident SE lasting ≥30 min, admitted between 2006 and 
2013. 
Measurements and main results: We recorded prospectively demographics, clinical SE features, 
treatment and outcome at discharge, and retrospectively medical comorbidities, hospital stay, 
and infectious complications. Associations between potential predictors and clinical outcome 
were analyzed using multinomial logistic regressions. Of 467 patients with incident SE, 238 
returned to baseline (51.1%), 162 had new disability (34.6%), and 67 died (14.3%); 50 subjects 
(10.7%) were managed with TC. TC was associated with poorer outcome in the whole cohort 
(relative risk ratio for new disability: 6.86, 95% CI: 2.84-16.56; for mortality: 9.10, 95% CI: 3.17-
26.16); the effect was more important in patients with complex partial, compared to generalized-
convulsive or nonconvulsive SE in coma. Incidence of infections was higher (OR 3.81, 95% CI: 
1.66-8.75) and median hospital stay in patients discharged alive was longer (16 days [range 2-
240] vs. 9 days [range 1-57], p<0.001) in subjects managed with TC. 
Conclusions: This study provides Class III evidence that TC is associated with poorer outcome 
after SE; furthermore, it portends higher infection rates and longer hospitalizations. These data 
suggest caution in the straightforward use of this approach, especially in patients with complex 
partial SE. 
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Introduction 
Status epilepticus (SE) is the second most frequent neurological emergency after stroke, with 
an important risk of morbidity and mortality [1-3]. Treatment recommendations for SE are based 
on a three-step approach [4, 5]; in this context, SE not responding to benzodiazepines (first-line 
therapy) followed by an antiepileptic drug (second-line therapy) is commonly labeled as 
refractory SE (RSE). This condition occurs in 23% to 43% of patients with SE [6, 7], and 
management with therapeutic coma (TC) is advocated in current guidelines (third-line therapy) 
[4, 5, 8, 9], although there is no high-level evidence.  
The effective impact of third-line therapy on outcome, however, has not been clearly 
established. Recently, a cohort study of 126 patients with SE suggested that this approach may 
be associated with poorer outcome and death [10], but this analysis was not adjusted for all 
known principal outcome predictors. Another study including 54 subjects with RSE showed that 
longer duration of TC is associated with unfavorable prognosis [11]; however, this cohort was 
restricted to a neurologic intensive care unit (ICU) environment and the authors did not adjust 
for SE outcome predictors. Conversely, in a cohort of 111 patients, use of general anesthetics 
did not have any impact on mortality; here again the patients were evaluated only in ICU 
settings and interaction with SE refractoriness was not assessed [12]. Finally, a study by the 
same group recently showed that use of anesthetic agents is related to worse outcome; again, 
this analysis was limited to an ICU setting [13]. These divergent observations and the related 
methodological limitations (including a retrospective approach in most studies) prevent a 
conclusive judgment upon the impact of coma induction on SE outcome, independently from the 
underlying cause and the severity of the episode. 
The objective of this study was to assess the specific impact of TC on prognosis of patients with 
SE, without restriction to ICU, after adjustment for the most important prognostic factors. 
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Material and Methods 
Cohort definition 
We included consecutive adult patients (older than 16 years old) with SE, admitted to our center 
between April 1, 2006 and July 30, 2013 (88 months), who were prospectively enrolled in our 
registry that received full approval from our Ethic commission. Cases with postanoxic etiologies 
were not enrolled in our registry. SE was defined as the occurrence of continuous seizures or 
repetitive seizures between which there is incomplete recovery of baseline clinical conditions for 
≥30 min (until 2008) and for ≥5 min (since 2008). SE episodes were clinically diagnosed by 
neurology consultants and confirmed with electroencephalogram (EEG) studies, which was 
mandatory for non-convulsive forms. Further details on this registry have been published 
previously [6]. This study considered only incident cases of SE which lasted ≥30 min, in order to 
avoid over-representation of certain individuals and include only episodes with consistent 
prognostic implications. 
Variables 
Age, gender, and history of previous seizures were prospectively recorded on admission. 
Etiology leading to death if not specifically treated was categorized as “potentially fatal” as 
previously detailed [15]. Level of consciousness before treatment was categorized as alert, 
confused or somnolent (arousable towards a clear clinical contact), stuporous (arousable, but 
without contact), and comatose; the latter two were classified as “severe impairment of 
consciousness”. Type of SE was defined by the worst clinical seizure in the given episode and 
classified, in increasing order of severity, as simple partial (focal without consciousness 
impairment), absence, myoclonic (related to genetic generalized epilepsy), complex partial 
(focal with consciousness impairment), generalized convulsive SE (GCSE), or non-convulsive 
SE in coma (NCSEC). GCSE episodes were further dichotomized into “proper” GCSE (those 
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which presented prolonged generalized convulsive seizures up to the SE diagnosis and 
treatment) and “GCSE then focal” (those with focal seizures without coma on diagnosis, but 
having presented an earlier generalized convulsion during the same episode), as we 
hypothesized that these two forms might have different prognostic implications. The SE severity 
score (STESS), a validated clinical scoring system considering age, worst seizures type, level of 
consciousness impairment, and history of previous seizures, was calculated for each patient on 
admission [16, 17]. 
We prospectively recorded use of therapeutic coma for SE treatment, specific anesthetic agents 
administered in each episode, and treatment latency (representing the best estimated time from 
SE onset to administration of the first medication and dichotomized at 1 hour following the 
beginning of the SE episode). Therapeutic coma was a clinically driven endpoint, monitored by 
EEG (with seizure suppression, or burst suppression, as target), and it was accomplished using 
anesthetic drugs as continuous intravenous drips. Our hospital is a third level center including a 
multidisciplinary ICU; patients with SE are mostly treated in the neurology ward (intermediate 
care unit) and admitted to the ICU if they need mechanical ventilation. The main clinical 
outcome, prospectively assessed at hospital discharge, was categorized into three groups: 
return to baseline, new disability (defined as new neurological impairment, as compared to the 
situation before the incident SE episode), or death. 
By screening the computerized hospital database, medical comorbidities were retrospectively 
retrieved after discharge using the 17-items version of the Charlson Comorbity Index (CCI), 
using International Statistical Classification of Disease and Related Health Problems, 10th 
Revision (ICD-10) coding algorithms [18, 19]; medical conditions considered as SE etiology for 
the specific episode were excluded from CCI, in order to avoid redundancy. Duration of acute 
hospital stay (defined as ICU and acute neurology ward stay) was also retrospectively retrieved 
in selected patients (see below), as was the occurrence of infectious complications requiring 
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antibiotics (classified into respiratory tract, urinary tract, bloodstream, or others) arising during 
SE treatment (infections occurring prior to SE or after SE treatment were not considered). 
Statistical analysis  
The association between potential predictors and clinical outcome was analyzed using 
univariable multinomial logistic regressions. Multinomial (polytomous) logistic regression fits 
maximum likelihood models with discrete dependent variables, when the dependent variable 
takes on more than two outcomes and the outcomes have no natural ordering, as in the present 
study (see suppl. material). Outcome prognosticators with a p<0.05 were used in a backward 
procedure to fit a multivariable multinomial model. Results were described with relative risk 
ratios (RRR) and 95% confidence intervals (CI). We conducted analyses in the complete cohort, 
as well as in patients with GCSE “proper” or NCSEC vs. other SE forms. 
Incidence of infectious complications was analyzed in a nested case-control assessment 
comparing all patients managed with TC and a control group of the same number of subjects 
treated without TC, matched for outcome, potentially fatal etiology, STESS, and CCI; results are 
given in odds ratio (OR) and 95% CI. The same approach was used to analyze the length of 
hospital stay using a Wilcoxon test; patients who died were excluded from this analysis, in order 
to avoid bias of shorter hospitalization. We chose to adjust for the aforementioned variables in 
order to specifically address the role of TC (exposure) on infections, respectively duration of in-
hospital stay (outcomes), as clinical outcome may confound these relationships. The use of 
specific anesthetic drugs for coma induction was investigated with a Fisher’s exact test 
comparing the three outcome groups. Analysis was performed using the Stata software version 
12 (College Station, TX); significance was considered at p<0.05. 
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Results 
During the 88 months study period, we identified 467 incident episodes of adult SE lasting ≥30 
min (representing 77.2% of 606 events in our registry; 52 episodes lasting <30 minutes and 86 
recurrent episodes were excluded). Mean age was 60.3 years (SD ± 18.6) and 228 were 
women (48.8%). An overview of the clinical characteristics of patients according to functional 
outcome is presented in Table 1. At hospital discharge, half of patients returned to baseline 
conditions (51.0%), one-third had a new disability (34.7%), and mortality occurred in 14.3%. 
Fifty subjects (10.7%) were managed with therapeutic coma. Of the 67 patients who died, 23 
died during SE and 7 had anesthetic treatments (4 propofol, 3 thiopental). A potentially fatal 
etiology was identified in 237 episodes; the most frequent occurrences were 50 (21.1%) primary 
brain tumors (mostly glioblastoma multiforme), 44 (18.6%) intracranial hemorrhages, 35 (14.8%) 
metastatic brain tumors, and 22 (9.3%) encephalitis or meningoencephalitis. On univariable 
analysis, worse outcome occurred more frequently in elderly subjects, as well as in patients 
having no history of previous seizures, a potentially fatal etiology, a severe impairment of 
consciousness, a higher STESS, a higher CCI, and TC for SE treatment.  
The most common forms of SE encountered in our cohort were complex partial SE and “proper” 
GCSE (representing each about one third of the cohort); clinical characteristics of patients 
according to TC is shown in Table 2. Of note, there was no significant difference among the 
three outcome groups concerning the specific anesthetics agents used for coma induction 
(Table 3).  
The multivariable model showed that the risk for new disability was independently higher in 
patients with increasing age, lack of previous seizures, a potentially fatal etiology, and TC. 
Furthermore, age, potentially fatal etiology, STESS, CCI, and TC were independently 
associated with mortality (Table 4). The relationship between these predictors and mortality was 
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also explored in the subgroups of patients with “proper” GCSE and NCSEC, versus other SE 
forms (Figure 1). After adjustment for the other predictors, TC for SE treatment was significantly 
related to outcome in both groups, but the effect magnitude tended to be higher among patients 
with complex partial SE forms at the time of treatment initiation. 
Regarding the nested case-control assessment, among the 50 patients treated with TC the 
incidence of infectious complications was higher than in the 50 matched controls (31 vs. 15, 
OR=3.81, CI (95%): 1.66-8.75). Most (38; 64.4%) were lower respiratory tract infections, 
followed by urinary tract (11; 18.6%), and sepsis (10; 17%; some were combined in the same 
patient). Moreover, the median acute hospital stay was significantly longer in the 37 patients 
discharged alive and managed with this approach, than in the control group composed of 37 
matched surviving subjects (16 days [range: 2-240] vs. 9 days [range: 1-57], p<0.001, 
Wilcoxon). 
 
Discussion 
The principal finding of this study is that TC administered for SE treatment is associated with a 
worse clinical outcome, including mortality, after taking into account the etiology and severity of 
the underlying condition; this relationship (Class III evidence) appears stronger in patients with 
forms of SE other than “proper” GCSE and NCSEC. In addition, subjects treated with this 
approach displayed higher infection rates, and longer acute hospital stay when discharged alive. 
TC is advocated in current guidelines for management of SE, although its impact on functional 
outcome has not been clearly established, and somewhat surprisingly has received relatively 
little attention to date. This approach has been reported to be related to worse prognosis [10, 
13], especially if lasting for many days [11], but not invariably  [12] (although in this study 
interaction with SE refractoriness was not assessed). All these analyses had a retrospective 
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design and findings were not adjusted for all known outcome predictors, especially potentially 
fatal etiology; it is also at times unclear how recurrent cases were handled. Moreover, in three of 
those studies [11],[12, 13], the analyzed cohort was exclusively composed of patients seen in 
ICUs, thus potentially limiting the generalizability; this is highlighted by the higher rate of 
administration of anesthetic agents (33%-87%) and prevalence of GCSE and NCSEC (46%-
92%) as compared to the present cohort (11%, respectively 46%).  
In the present study, the prognostic impact of TC in 467 consecutive adult patients with incident 
SE was investigated after adjustment for all major prognostic factors, such as etiology [15, 20, 
21], STESS (including age, seizures type, consciousness impairment and history of previous 
seizures) [16, 17], and comorbid conditions assessed with the CCI [22, 23]; of note, apart from 
the CCI, the aforementioned variables were recorded prospectively. The combination of these 
variables has recently been shown to account for more than 90% of the mortality prediction [24]; 
their predictive robustness is consistently found across studies [25], and seems further 
confirmed by our findings. We also adjusted for age and lack of previous seizures. TC was 
significantly related to outcome in the whole cohort, and this relationship turned out to be even 
more important in the subgroup of patients with forms of SE others than “proper” GCSE or 
NCSEC: the vast majority of patients in this group were diagnosed with complex partial SE, an 
SE form felt to be less dangerous in terms of prognostic implication [26-28].  
 
There is an ongoing lively debate among experts about the need to proceed quickly to coma 
induction in patients with “non-convulsive” SE (including complex partial) [29]; some recent 
guidelines indeed recommend intensive care treatment with TC for refractory SE, without 
specifying whether specific forms need an adapted treatment [5]. The present finding suggests 
in fact that this approach may prove especially harmful in such patients. To our knowledge, this 
is the first study investigating in detail the impact of TC on prognosis focusing on different forms 
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of SE classified by semiology. Particularly, we differentiated “GCSE then focal” (those with focal 
seizures without coma on diagnosis, but having presented previously a generalized convulsion 
during the same episode) from “proper” GCSE (those presenting with prolonged generalized 
convulsions up to the SE diagnosis and treatment), as we hypothesized that the former might 
represent a form of SE with prognostic implications similar to complex partial SE. Our results, 
added to the aforementioned studies [10, 13],[11], seem thus to offer a rationale corroborating a 
relatively conservative therapeutic approach in patients without “proper” GCSE or NCSEC, in 
line with several expert opinions and recommendations suggesting to try additional non-
sedating antiepileptic drugs before considering coma induction in these patients [4, 30-32]. 
A potential consequence of using TC relates to a higher risk of complications, such as 
infections, and longer hospitalizations. A recent study considering 160 subjects with SE in an 
ICU environment showed that infections were related to longer SE duration, longer ICU stay, 
higher risk of RSE, and higher mortality; the overall infection rate was 23% [33]. This was 
confirmed in the recent analysis by the same group[13]. Indeed we also observed a significant 
higher infection rate in patients treated with TC. Hospitalization length has been suggested to 
increase in SE patients needing airway intubation [34]. Moreover, among 54 patients with RSE, 
mean duration of coma was 11.0 days and mean hospital stay was 27.7 days [11]; and recently 
a longer hospitalization in patients treated with coma induction was showed [13], but without 
accounting for bias resulting from mortality. In our nested case-control study, acute 
hospitalization was significantly longer among surviving patients treated with TC as compared to 
matched controls. This finding implies potential major practical consequences, since prolonged 
hospitalization may expose patients to medical complications [33] and induce additional health 
care costs.  
Our study has of course limitations. First, it is based on a single tertiary center cohort, and some 
data (such as CCI, acute hospital stay, and infection rates) were retrospectively retrieved. 
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However, we used a prospective registry for all other data (representing the most important 
prognostic variables), with homogeneous assessment criteria over the entire recruitment period, 
and the retrospectively added data were recorded by the same author (NAM), elements that in 
our view corroborate its internal validity. Moreover, to the best of our knowledge our study 
represents the largest cohort of SE adult patients, with the advantage of being representative of 
the SE population seen in a hospital, as it was not restricted to particular SE forms or an ICU 
environment: while of course patients with mechanical ventilation are found in the ICU, subjects 
with refractory SE managed outside the ICU were included in this study, as they represent a 
situation found in clinical practice (in fact, in our center patients not needing mechanical 
ventilation are mostly managed in intermediate care units). Second, as TC allocation was not 
randomized, we cannot formally exclude additional, not yet identified confounding factors. 
Particularly, we acknowledge that patients treated with TC were probably felt more ill, in some 
way that might not always have been accounted for by the analyses. However, multivariate 
analyses were used to adjust for the most important known outcome predictors (which together 
account for over 90% of SE prognosis [24]), reducing this risk. Third, we investigated the effect 
of TC on functional outcome at hospital discharge, but we cannot exclude that long term 
prognosis might have changed. Therefore, we also used mortality during the hospital stay, 
which represents a robust, non-debatable outcome. Additionally, our mortality rate of 14.3% 
corroborates the present findings, lying in the middle range as compared to several prospective, 
population-based studies [1, 2, 35]. Fourth, treatment latency represents an estimate, as SE 
onset is sometimes subtle or unclear (especially in patients with out-of-hospital SE onset); 
nonetheless, there was no significant difference among the outcome groups and it was not 
taken into account for the multinomial logistic regression (being nonsignificant in the univariable 
approach). Finally, we unfortunately do not have information regarding coma duration (but we 
retrieved hospitalization length in the nested case-control study), and specific EEG patterns, 
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and we did not adjust for treatment options before TC; however, medication appropriateness 
seems to play a negligible role in the prognosis of SE [24, 36]. 
 
Conclusion 
This study shows that TC is associated with mortality, poorer functional outcome, higher 
infection rates, and longer acute hospital stay after adjustment for the most important outcome 
predictors, and thus suggests caution in the straightforward use of this therapeutic approach, 
particularly in patients with complex partial SE at the moment of diagnosis. However, we 
acknowledge that factors like severe impairment of consciousness with loss of airways 
protection or durable generalized convulsive seizure leading to neuronal injury may direct the 
risk-benefit scale in favor of TC. Accordingly, the use of this approach for patients with GCSE or 
NCSEC appears fully justified. Multicenter, prospective studies are needed to better identify 
which further category of SE patients would take the best advantage from this approach, since 
the feasibility of a randomized trial in this setting unfortunately appears very unlikely [37]. 
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Table 1 Demographics and clinical characteristics of 467 patients with incident status 
epilepticus, according to clinical outcome at hospital discharge. Bold values are significant. 
 Return to baseline 
(n = 238) 
New disability 
(n = 162) 
Death 
(n = 67) 
New disability vs. 
Return to baseline 
RRR, CI (95%), P 
value 
Death vs. Return to 
baseline 
RRR, CI (95%), P 
value 
Age (years; mean, ± 
SD)  
54.9 ± 18.9 65.3 ± 16.4 67.5 ± 17.1 1.03,  (1.02-1.05), 
P<0.001 
1.04, (1.02-1.06), 
P<0.001 
Female gender (n = 
228)  
112 (47.1%) 84 (51.8%) 32 (47.8%) 0.83, (0.55-1.23), 
P=0.347 
0.97, (0.56-1.67), 
P=0.919 
Previous seizures (n = 
199) 
138 (58.0%) 42 (25.9%) 19 (28.4%) 0.25, (0.16-0.39), 
P<0.001 
0.29, (0.16-0.52), 
P<0.001 
Potentially fatal 
etiology (n = 237)  
83 (34.9%) 100 (61.7%) 54 (80.6%) 3.01, (1.99-4.56), 
P<0.001 
7.76, (4.00-15.03), 
P<0.001 
Proper GCSE or 
NCSEC (n = 180)  
92 (38.7%) 59 (36.4%) 29 (43.3%) 0.91, (0.60-1.37), 
P=0.651 
1.21, (0.70-2.10), 
P=0.494 
Severe impairment of 
consciousness (n = 
257)  
119 (50.0%) 89 (54.9%) 49 (73.1%) 1.22, (0.82-1.82), 
P=0.332 
2.72, (1.50-4.95), 
P=0.001 
STESS (median, 
[range])  
2 [0;5] 3 [0;6] 3 [1;6] 1.61, (1.38-1.89), 
P<0.001 
2.09, (1.66-2.62), 
P<0.001 
Charlson Comorbidity 
Index  (median, 
[range])  
0.5 [0;10] 1 [0;9] 3 [0;8] 1.10, (1.01-1.21), 
P=0.028 
1.29, (1.16-1.44), 
P<0.001 
Treatment latency > 1 
hour (n = 312)  
150 (63.0%) 113 (69.8%) 48 (71.6%) 1.35, (0.88-2.07), 
P=0.165 
1.48, (0.82-2.68), 
P=0.193 
Therapeutic coma (n = 
50)  
10 (4.2%) 27 (16.7%) 13 (19.4%) 4.56, (2.14-9.71), 
P<0.001 
5.49, (2.29-13.18), 
P<0.001 
CI = confidence interval; RRR = relative risk ratio; GCSE = generalized convulsive status 
epilepticus; NCSEC = nonconvulsive status epilepticus in coma; SE = status epilepticus; STESS 
= status epilepticus severity score 
  
 
Table 2 Demographics and clinical characteristic of patients with and without therapeutic coma. 
 
 All patients (n = 467) Patients without 
therapeutic coma (n = 
417) 
Patients with therapeutic 
coma (n = 50) 
Age (years; mean, ± SD) 60.3 ± 18.6 60.7 ± 18.5  57.2 ± 19.2 
Female gender 228 (48.2%) 204 (48.9%) 24 (48%) 
Potentially fatal etiology 237 (50.7%) 210 (50.4%) 27 (54%) 
STESS (median, range) 3 (0-6) 3 (0-6) 3 (1-6) 
Type of SE    
- Simple partial 91 (19.5%) 91 (21.8%) - 
- Absence 7 (1.5%) 7 (1.7%) - 
- Myoclonic 1 (0.2%) 1 (0.2%) - 
- Complex partial 154 (33.0%) 144 (34.5%) 10 (20.0%) 
- GCSE then partial 34 (7.3%) 30 (7.2%) 4 (8.0%) 
- Proper GCSE 155 (33.2%) 130 (31.2%) 25 (50.0%) 
- NCSEC 25 (5.4%) 14 (3.4%) 11 (22.0%) 
SE = status epilepticus; GCSE = generalized convulsive status epilepticus; NCSEC = 
nonconvulsive status epilepticus in coma; STESS= status epilepticus severity score. 
 
 
 
Table 3 Clinical outcome in 50 patients categorized by the anesthetics used for therapeutic 
coma.  
 Return to 
baseline (n = 10) 
New disability (n 
= 27) 
Death (n = 13) P value (*) 
Propofol 8 (80.0%) 26 (96.3%) 11 (84.6%) 0.186 
Midazolam 2 (20.0%) 9 (33.3%) 4 (30.8) 0.844 
Thiopental  1 (10.0%) 3 (11.1%) 3 (23.1%) 0.552 
Ketamine 0 (0.0%) 2 (7.4%) 0 (0.0%) 0.713 
(*) = Fisher’s exact test 
 
Table 4 Identified variables associated with clinical outcome in 467 adults with incident SE from 
the fitted multivariable model. Results are given as relative risk ratio (RRR) and 95% confidence 
interval (CI), as compared to return to baseline clinical conditions. Variables with P<0.05 in the 
univariable analysis were retained for the multivariable assessment. Bold values are significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SE = status epilepticus; GCSE = generalized convulsive status epilepticus; NCSEC = 
nonconvulsive status epilepticus in coma; STESS = status epilepticus severity score 
 
 
 
 New disability Mortality 
Age 1.03 (1.01-1.05) 1.03 (1.01-1.05) 
Lack of previous 
seizures 
2.48 (1.49-4.15) 1.35 (0.66-2.78) 
Potentially fatal 
etiology 
2.72 (1.70-4.35)  7.2 (3.45-15.04) 
STESS 1.12 (0.92-1.38) 1.56 (1.17-2.10) 
Charlson Comorbidity 
Index  
1.02 (0.92-1.13) 1.18 (1.05-1.33)  
Therapeutic coma 6.86 (2.84-16.56)  9.10 (3.17-26.16)  
Figure 1 Relative risk ratio of therapeutic coma for new disability and mortality, in the whole 
cohort, in patients with proper generalized convulsive or nonconvulsive SE in coma, and in 
patients with other SE forms. 
 
 
 
 
SE = status epilepticus; GCSE = generalized convulsive status epilepticus; NCSEC = 
nonconvulsive status epilepticus in coma; grey diamonds = new disability; black squares = 
mortality. 
 
 
 
